Upbeat Outlook For TCM Industry
This article was originally published in PharmAsia News
The Chinese government issued several policies and statutes to support the development of traditional Chinese medicine, breathing fresh life into the sector. Analysts predict that both traditional Chinese medicine sales revenues and profits are expected to grow more than 20 percent in 2008 due to several factors: Per capita health care expenditure is climbing steadily; the government is increasing investment to promote the modernization and internationalization of TCM; health reforms and medical insurance for urban and rural communities could potentially expand the medical market to 100 billion yuan; and a lower standard tax rate of 25 percent for domestic and foreign-funded companies, which will raise the profitability of the TCM industry. (Click here for more - Chinese Language)
You may also be interested in...
SHANGHAI - China Shenghuo Pharmaceutical will launch its new traditional Chinese medicine-based 12Ways Skin Care products in the U.S. during the first quarter of 2008, the company announced Feb. 7
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.